Global Cervical Cancer Diagnostics Market - 2023-2030

Market Overview

The Global Cervical Cancer Diagnostics Market size reached USD 8.1 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 13 billion by 2030. The cervical cancer diagnostics market is expected to exhibit a CAGR of 6.3% during the forecast period 2023-2030.

A variety of tests and techniques are employed in the diagnosis and monitoring of cervical cancer and precancerous diseases as part of cervical cancer diagnostics. Additional procedures, such as lymph node biopsy, cystoscopy, proctoscopy or imaging tests like PET-CT (positron emission tomography-computed tomography), are carried out to ascertain the stage of cervical cancer.

Market Dynamics

Active Major Players and Cervical Cancer Diagnostic Product Launches are Boosting the Global Cervical Cancer Diagnostics Market Growth During the Forecast Period.

For women, cervical cancer is a typically malignant tumor. In recent years, there has been an apparent trend of rejuvenation along with an increase in morbidity and mortality. The only cancer that has a clear etiology and may be cured with early detection is cervical cancer. For instance, the CerviClear test, developed by New Horizon Health, is the world's first urine-based HPV detection and cervical cancer screening test.

It accomplishes non-invasive home-based urine self-sampling and is the only solution that completely covers all 14 high-risk HPV viruses. The product is eligible to be introduced in Hong Kong and the Greater Bay Area because it already possesses a CE Mark.

The Growing Awareness Among Consumers About Cervical Cancer is Boosting the Global Cervical Cancer Diagnostics Market Growth During the Forecast Period.

Cervical cancer is one of the most preventable cancers, it accounts for nearly 77,000 deaths among Indian women each year. For instance, in April 2023, the Cancer Awareness Prevention and Early Detection Trust (CAPED), a non-profit organization dedicated to promoting cancer awareness, prevention, and early detection, and Roche Diagnostics India signed a Memorandum of Understanding (MoU).

The relationship with CAPED is one recent initiative by Roche Diagnostics India to remove the societal stigma associated with the disease and raise awareness about cervical cancer screening. Roche Diagnostics India is dedicated to reducing the incidence of cervical cancer internationally.

The High Cost of Diagnostic Tests is Hampering the Global Cervical Cancer Diagnostics Market Growth in the Forecast Period.

The price of cervical cancer diagnostic tests can vary depending on several variables, including the particular test, location, the environment for the medical facility and the healthcare system in existence. Pap tests can cost from $20 and $100, depending place and healthcare professionals.

In addition, HPV DNA tests cost from $50 to $200 or more, depending on the lab and the precise testing technique employed. A colposcopy operation might cost between $200 and $800, depending on the area, the healthcare professional and any extra procedures carried out during the examination.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the cervical cancer diagnostics market. The pandemic has put pressure on healthcare systems, which has restricted the availability of cervical cancer diagnostic services.

Delays in diagnostic testing, such as Pap smear tests, HPV tests, colposcopies and biopsies, have been attributed to a lack of resources, overburdened healthcare institutions and the redirection of workers to COVID-19 response operations.

As of 2023, the COVID-19 situation is recovering and all patients can access healthcare facilities driving the cervical cancer diagnostics market.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the cervical cancer diagnostics market is complex and multifaceted. People may be displaced by the combat, transportation may be disrupted, and military checkpoints may be set up. These obstacles may limit access to medical facilities, making it difficult for people to get prompt cervical cancer diagnoses and other healthcare services.

In addition, healthcare resources and efforts were redirected during times of conflict to focus on trauma care, emergency response and urgent medical needs. This results in fewer public health measures, such as awareness campaigns and cervical cancer screening programs, which would lower screening rates and postpone diagnosis.

Segment Analysis

The global cervical cancer diagnostics market is segmented based on test type, age group, distribution channel, end-user and region.

The HPV DNA Test Segment is Expected to Hold the 2nd Dominant Position in the Market Over the Forecast Period.

The HPV DNA test segment accounted for the 2nd highest market stake accounting for approximately 27.6% of the cervical cancer diagnostics market in 2022. An HPV test examines a sample of cells to see if they have a high-risk form of the virus. If such an infection persists for a long time, it may alter cervical cells and result in cervical cancer.

For instance, in September 2022, to test for high-risk HPV types in individuals, Mylab Discovery Solutions introduced the "PathoDetect HPV Detection Test," a real-time PCR-based screening tool. 'PathoDetect HPV Detection Test' is a regulatory authority-approved test that finds and distinguishes the presence of high-risk HPV strains, such as strains 16 and 18, which are responsible for the majority of cervical cancers.

Geographical Analysis

Increasing Collaborations and Partnerships Among the Key Players, Increasing Prevalence of Cervical Cancer and Advancement in Cervical Cancer Diagnostics Dominate the North American Region.

North America is expected to dominate the cervical cancer diagnostics market, accounting for around 38.9% of the market share. As per the article published in the International Journal of Gynecological Cancer in 2022, when examining the trends over time, it was discovered that the prevalence of cervical cancer in its remote stages increased annually at a rate of 1.3% (p 0.001). Cervical adenocarcinoma has the highest growth, with an average yearly percent change of 2.9% (p 0.001).

White women in the South aged 40-44 have the biggest increase in distant cervical cancer at a rate of 4.5% annually (p0.001), according to an intersecting analysis of race, location and age.

Competitive Landscape

The major global players in the market include: QIAGEN Becton, Dickinson and Company F. Hoffmann-La Roche Ltd. Guided Therapeutics Olympus Cardinal Health Siemens Healthcare Hologic, Inc. Quest Diagnostics Abbott Laboratories among others.

Why Purchase the Report?

• To visualize the global cervical cancer diagnostics market segmentation based on the test type, age group, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of cervical cancer diagnostics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Cervical Cancer Diagnostics Market Report Would Provide Approximately 61 Tables, 60 Figures and 195 pages.

Target Audience 2023

• Manufacturers / Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies